Thinking small: challenges and opportunities for non-antibody scaffold drugs
The first candidates from the promising class of small non-antibody protein scaffolds are now moving into clinical development and practice. Challenges remain, and scaffolds will need to be further tailored toward applications where they provide real advantages over established therapeutics to succeed in a rapidly evolving drug development landscape.
|Authors||Vazquez-Lombardi, R.; Phan, T. G.; Zimmermann, C.; Lowe, D.; Jermutus, L.; Christ, D.|
|Responsible Garvan Author|
|Publisher Name||DRUG DISCOVERY TODAY|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/26360055|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/12290|